FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DCAL Consensus Forecast

No. of reports in last year
6
No. of analysts
2
Average Consensus Forecast
267.33
Consensus Potential
47.53%

DCAL Price Target Potential

BrokerageTargetPotential
Nirmal Bang18531.38%
HDFC Securities35063.73%

DCAL Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for DCAL
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

DCAL Ratings

Long term DCAL rating by FrontPage users
5/5 (5 Ratings)

6 DCAL share price target reports by brokerages below. See what is analyst's view on DCAL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. DCAL Forum
  3. DCAL Price Target

DCAL Share Price Target

DCAL Share Price Target - Broker Reports - 2020

28-Jan-20
Price @ Call: 83.6
Target: 185
BUY
Dishman Carbogen Amcis’ or DCAL’s 3QFY20 revenue at Rs5,423mn is 2.2% below our and 4.4% above consensus estimate. The Company had an EBITDA of Rs1,254 ( lower by 5.6% QoQ) and below our/consensus estimates by 22.4%/15.4%, respectively. Net profit at Rs329mn is below our/consensus estimate by 39.6%/37.1%, respectively. The margins were subdued in this quarter due to a higher proportion of CRAMS revenue coming from international operations. The gross margins were lower around 800bps QoQ, but for the full year it is expected to be in the range of 79-81%. In addition to higher cost of sales, employee expenses increased 10% QoQ as during the quarter, the company recorded annual bonus pay outs.
... Read more

DCAL Share Price Target - Broker Reports - 2019

27-Dec-19
Price @ Call: 80.74
Target: 185
BUY
25-Oct-19
Price @ Call: 118.35
Target: 185
BUY
We have rolled over our valuation and shift from EV/EBITDA based valuation methodology to P/E based. We have adjusted our EPS for IND AS 116 Impact and have lowered our growth estimates for CRAMs business. We assign a 10x PE multiple to September 2021 earnings to arrive at a target price of Rs185 (from Rs369 earlier).
... Read more
20-Sep-19
Price @ Call: 172.35
Target: 350
BUY
We remain constructive on DCAL owing to strong visibility on its order book, 15+ late phase 3 molecules, expanded development capacity, ability to work on new molecules like ADCs, and favorable currency. Improvement in BS driven by reduced debt and working capital release would be one of the important parameters to drive re-rating of the stock. At CMP, the stock is trading at 10.1/7.8 FY19/20E, a ~60% discount to peers like Divi’s Labs. Maintain BUY with a TP of Rs 350 (15x FY21E EPS).
... Read more
19-Aug-19
Price @ Call: 178
Target: 355
BUY
We maintain a BUY on DCAL following a disappointing quarter. Our TP is revised to Rs 355 (15x FY21E EPS) with a 5% cut to FY21E EPS (higher depreciation expectation).
... Read more
16-Aug-19
Price @ Call: 178.12
Target: 344
BUY
Despite a weak quarter, the company has maintained its full year guidance of 10% growth in revenue and EBITDA margin in the range of 26%-27%. Our forecasts assume revenue and EBITDA margin slightly above the guidance range. However, considering the market conditions, we lower our target valuation multiple on DCAL to 9x EV/EBITDA from 11x EV/EBITDA and arrive at a target price (TP) of Rs344.
... Read more
20-May-19
Price @ Call: 215.75
Target: 390
BUY
We expect revenue and PAT CAGRs over FY19-21 of respectively ~12% and ~19%. We maintain a Buy, with a higher target of Rs 390 based on FY21e EPS.
... Read more
28-Jan-19
Price @ Call: 216.25
Target: 320
BUY
28-Jan-19
Price @ Call: 216.25
Target: 429
BUY
28-Jan-19
Price @ Call: 216.25
Target: 380
BUY

DCAL Share Price Target - Broker Reports - 2018

7-Dec-18
Price @ Call: 237.12
Target: 355
BUY
1-Oct-18
Price @ Call: 236.54
Target: 415
BUY
31-Jul-18
Price @ Call: 261.3
Target: 380
BUY

DCAL Share Price Target - Broker Reports - 2017

26-Dec-17
Price @ Call: 317.56
Target: 435
BUY
13-Nov-17
Price @ Call: 293.75
Target: 410
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DCAL Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3156.03
    Upside Target 2147.82
    Upside Target 1141.73
    Pivot133.52
    Downside Target 1127.43
    Downside Target 2119.22
    Downside Target 3113.13
  • DCAL Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3151.52
    Upside Target 2142.98
    Upside Target 1134.97
    Pivot126.43
    Downside Target 1118.42
    Downside Target 2109.88
    Downside Target 3101.87
  • DCAL Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3226.37
    Upside Target 2182.18
    Upside Target 1151.97
    Pivot107.78
    Downside Target 177.57
    Downside Target 233.38
    Downside Target 33.17
  • DCAL Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3147.82
    Upside Target 2142.35
    Upside Target 1138.98
    Pivot133.52
    Downside Target 1128.05
    Downside Target 2124.68
    Downside Target 3119.22
  • DCAL Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3142.98
    Upside Target 2136.66
    Upside Target 1132.76
    Pivot126.43
    Downside Target 1120.11
    Downside Target 2116.21
    Downside Target 3109.88
  • DCAL Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3182.18
    Upside Target 2153.76
    Upside Target 1136.2
    Pivot107.78
    Downside Target 179.36
    Downside Target 261.8
    Downside Target 333.38
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020